Drugs / Theracal LC
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT05733468 | Jul 2022 → Mar 2024 | dental caries, pulpitis | Postgraduate Institute of Dental Sciences Rohtak | Unknown | No outcome recorded |
| Phase 4 | NCT05167123 | Sep 2019 → Nov 2021 | dental caries, pulpitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04397094 | Dec 2017 → Mar 2018 | dental caries | Ain Shams University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03606681 | Jul 2013 → Jun 2014 | dental pulp disorder | Altinbas University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06435065 Comparator | Apr 2024 → Apr 2025 | pulpitis | DR SURINDER SACHDEVA | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Theracal LC | “TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe” NCT05167123 ↗ |
| Modality | Other / unclassified | “Light cured silicate based cement (theracal LC) pulpotomy was compared to formocresol pulpotomy in primary molars.” NCT04397094 ↗ |